Csl112 drug
WebMar 22, 2024 · Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) The safety and scientific validity of this study is the responsibility of the … WebThe CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2024 Feb;208:81-90. doi: 10.1016/j.ahj.2024.11.008. Epub 2024 Nov 22.
Csl112 drug
Did you know?
WebYou received your blood test result with a Cholesterol value of 112 mg/dL. This analysis helps you to check if your Cholesterol value is within normal range. Cholesterol 0 … WebThis is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment …
WebCSL112 is a reconstituted, infusible human plasma-derived apolipoprotein A-I (apoA-I) that increases cholesterol efflux capacity – an ex vivo measure of the ability of HDL to accept …
WebNov 5, 2024 · CSL112, Apolipoprotein A-I (Human), is a novel formulation of human plasma-derived apoA-I, the primary functional component of high-density lipoproteins (HDL). Studies have shown that an infusion... WebCSL112 is a reconstituted, infusible human plasma-derived apolipoprotein A-I (apoA-I) that increases cholesterol efflux capacity – an ex vivo measure of the ability of HDL to accept cholesterol from macrophages. Areas covered: This article reviews the pharmacology of CSL112 and its current clinical development status.
WebCSL112 is a novel formulation of human apoA-I. The apoA-I is reconstituted with phosphatidylcholine to form disc-shaped HDL particles, each bearing 2 molecules of human apoA-I and 110 molecules of phosphatidyl-choline.22 CSL112 preparations contain sucrose as a stabilizing agent. In ex vivo studies, CSL112 was an efficient
WebMar 30, 2024 · CSL112 (Human Apolipoprotein A-I) Infusion Rapidly Increases APOA1 (Apolipoprotein A1) Exchange Rate via Specific Serum Amyloid-Poor HDL (High-Density Lipoprotein) Subpopulations When Administered to Patients Post–Myocardial Infarction Arteriosclerosis, Thrombosis, and Vascular Biology otherwhere手办WebOct 25, 2024 · CSL112 is an investigational drug containing human purified apoA-I, formulated with phosphatidylcholine (PC) and stabilized with sucrose. 35 CSL112 is supplied sterile and lyophilized in an evacuated vial, and was reconstituted with 50 mL of water for injection and administered intravenously at doses of 2 g (1 vial) or 6 g (3 vials) over 2 ... rock island american legion baseballWebMar 16, 2024 · During the last decade, CSL112 has been extensively studied in Phase 1 and 2 trials and has shown promising results. In particular, CSL112 has been studied in the Phase 2b AEGIS trial... otherwhere 绀野WebJun 26, 2014 · In the single ascending dose (SAD) study, 58 subjects were randomized to receive CSL112 or placebo in a 3:1 ratio, 57 received a dose of study drug, and 56 completed the study. One subject was withdrawn before dose administration and another was withdrawn after dose administration because of an adverse event. otherwhere meaningWebNov 15, 2016 · CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction. Methods: rock island and mcnabWebMar 22, 2024 · A third agent, CSL112, has advanced to phase 3 at a dose roughly 25-times higher than CER-001 and four-times higher than MDCO-216 . This trial in patients with acute coronary syndrome will examine time to subsequent major adverse cardiovascular event (cardiovascular death, myocardial infarction, or stroke) and is due to finish and be … rock island ammunitionWebMar 26, 2024 · “CSL112 is an exciting new approach in cardiovascular medicine that may help protect our patients when they are most vulnerable.” Research showed that … otherwhere 鶴田紫月